Combining drug-disease and economic modelling to inform drug development decisions

被引：27
|
作者：
Poland, B [1 ]
Wada, R [1 ]
机构：
[1] Pharsight Corp, Mt View, CA 94040 USA
来源：
DRUG DISCOVERY TODAY | 2001年 / 6卷 / 22期
关键词：
D O I：
10.1016/S1359-6446(01)02014-1
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Drug-disease models and clinical trial simulations are increasingly being used to support trial design and treatment optimization decisions. Less widely recognized is their potential for guiding strategic development decisions. These decisions require economic valuation of the potential product profile of efficacy, safety, ease of use, and so on. This review presents a disguised case study that uses drug-disease modelling to generate a probabilistic forecast of a drug's profile. This allows a quantitative analysis of whether to pursue a once-a-day regimen for an antiretroviral being tested twice-a-day in Phase II trials, and if so, at what dose and for which market segments.
引用
收藏
页码：1165 / 1170
页数：6
相关论文
共 50 条
  • [21] The Complex Structure of the Pharmacological Drug-Disease Network
    Lopez-Rodriguez, Irene
    Reyes-Manzano, Cesar F.
    Guzman-Vargas, Ariel
    Guzman-Vargas, Lev
    ENTROPY, 2021, 23 (09)
  • [22] Computational drug repurposing to predict approved and novel drug-disease associations
    Khalid, Zoya
    Sezerman, Osman Ugur
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2018, 85 : 91 - 96
  • [23] Drug repositioning using drug-disease vectors based on an integrated network
    Lee, Taekeon
    Yoon, Youngmi
    BMC BIOINFORMATICS, 2018, 19
  • [24] Drug repositioning using drug-disease vectors based on an integrated network
    Taekeon Lee
    Youngmi Yoon
    BMC Bioinformatics, 19
  • [25] Drug-drug and drug-disease interactions in the ED: Analysis of a high-risk population
    Goldberg, RM
    Mabee, J
    Chan, L
    Wong, S
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 1996, 14 (05): : 447 - 450
  • [26] Suboptimal prescribing in elderly outpatients: Potentially harmful drug-drug and drug-disease combinations
    Zhan, CL
    Correa-de-Araujo, R
    Bierman, AS
    Sangl, J
    Miller, MR
    Wickizer, SW
    Stryer, D
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (02) : 262 - 267
  • [27] The Development of Practice Recommendations for Drug-Disease Interactions by Literature Review and Expert Opinion
    van Tongeren, Justine M. Z.
    Harkes-Idzinga, S. Froukje
    van der Sijs, Heleen
    Atiqi, Roya
    van den Bemt, Bart J. F.
    Draijer, L. Willem
    Hiel, Deline
    Kerremans, Adrian
    Kremers, Bart
    de Leeuw, Marc
    Olthoff, Marleen V.
    Pham, T. Kim-Loan
    Valentijn-Robertz, Ricky
    Tsoi, Kayan
    Wichers, Iris
    de Wit, Maaike
    Borgsteede, Sander D.
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [28] QUALIFICATION OF DRUG-DISEASE TRIAL MODELS UNDER THE DRUG DEVELOPMENT TOOL (DDT) DRAFT GUIDANCE: CAMD EXPERIENCE
    Romero, K.
    Stephenson, D.
    Hudson, L.
    Rogers, J.
    Polhamus, D.
    Ito, K.
    Qiu, R.
    Corrigan, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S99 - S99
  • [29] Drug-Disease Association Prediction Using Heterogeneous Networks for Computational Drug Repositioning
    Kim, Yoonbee
    Jung, Yi-Sue
    Park, Jong-Hoon
    Kim, Seon-Jun
    Cho, Young-Rae
    BIOMOLECULES, 2022, 12 (10)
  • [30] Systematic Evaluation of Drug-Disease Relationships to Identify Leads for Novel Drug Uses
    Chiang, A. P.
    Butte, A. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (05) : 507 - 510
12345